InVivo Therapeutics Holdings Corp. (NVIV) today announced that
the company will be giving a poster presentation and exhibiting at the 65th
Congress of Neurological Surgeons (CNS) Annual Meeting, to be held in
New Orleans, LA, September 26-30, 2015. The e-poster, titled “Novel
Surgical Procedure to Implant an Investigational Neuro-Spinal Scaffold
Following Myelotomy for Treatment of Acute Traumatic Spinal Cord Injury:
A Safety and Feasibility Study,” is co-authored by Lorianne Masuoka,
M.D., Kristin Neff, M.S., Thomas Ulich, M.D., and Alex Aimetti, Ph.D.
InVivo will also host a networking event at this meeting aimed at
engaging and connecting with current and potential Principal
Investigators in our clinical study. At this event, Dr. Nicholas
Theodore from Barrow Neurological Institute, who performed the first
implantation of the Neuro-Spinal Scaffold in a human patient, will be
discussing his case experience and narrating his surgical video as a way
to inform the neurosurgical community about our novel therapeutic
approach.
“As a leader in the development of therapies for spinal cord injury, it
is imperative that we continue to strengthen and expand our network in
the neurosurgical community. With a worldwide membership of over 8,000
members, the Congress of Neurological Surgeons is a leader in education
and scientific exchange that is dedicated to advancing neurosurgery, and
we are pleased to be presenting and exhibiting at their annual meeting,”
said Mark Perrin, InVivo’s CEO and Chairman.
A new CEO’s Perspective regarding building value through increased
exposure within the scientific and medical community can be found on the
InVivo Therapeutics website: http://www.invivotherapeutics.com/about-invivo/ceo-perspective/.
About the Neuro-Spinal Scaffold™
Following an acute spinal cord injury, the biodegradable Neuro-Spinal
Scaffold is surgically implanted at the epicenter of the wound and
is designed to act as a physical substrate for nerve sprouting.
Appositional healing to spare spinal cord tissue, decreased
post-traumatic cyst formation, and decreased spinal cord tissue pressure
have been demonstrated in preclinical models of spinal cord contusion
injury. The Neuro-Spinal Scaffold, an investigational device, has
received a Humanitarian Use Device (HUD) designation and is currently
being studied in an Investigational Device Exemption (IDE) pilot study
for the treatment of patients with complete (AIS A) traumatic acute
spinal cord injury. Neuro-Spinal Scaffold™ is a trademark of
InVivo Therapeutics.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold received the 2015
Becker’s Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. These statements can be
identified by words such as "believe," "anticipate," "intend,"
"estimate," "will," "may," "should," "expect,"
“designed to,” “potentially,” and similar expressions, and include
statements regarding the expected benefits, efficacy and future
clinical outcomes of the company’s Neuro-Spinal Scaffold and the impact
on the company of increased exposure within the scientific and medical
community.. Any forward-looking statements contained herein are based on
current expectations, and are subject to a number of risks and
uncertainties. Factors that could cause actual future results to differ
materially from current expectations include, but are not limited to,
risks and uncertainties relating to the company’s ability to
successfully open additional clinical sites for enrollment and to enroll
additional patients; the timing of the Institutional Review Board
process; the company’s ability to obtain FDA approval to modify its
pilot trial protocol or to conduct a future study; the company’s ability
to commercialize its products; the company’s ability to develop, market
and sell products based on its technology; the expected benefits and
efficacy of the company’s products and technology in connection with the
treatment of spinal cord injuries; the availability of substantial
additional funding for the company to continue its operations and to
conduct research and development, clinical studies and future product
commercialization; and other risks associated with the company’s
business, research, product development, regulatory approval, marketing
and distribution plans and strategies identified and described in more
detail in the company’s Annual Report on Form 10-K for the year ended
December 31, 2014, and its other filings with the SEC, including the
company’s Form 10-Qs and current reports on Form 8-K. The company does
not undertake to update these forward-looking statements.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150921005368r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20150921005368/en/
Copyright Business Wire 2015